KR20240004296A - 혈장 칼리크레인의 헤테로아릴 억제제 - Google Patents

혈장 칼리크레인의 헤테로아릴 억제제 Download PDF

Info

Publication number
KR20240004296A
KR20240004296A KR1020237034887A KR20237034887A KR20240004296A KR 20240004296 A KR20240004296 A KR 20240004296A KR 1020237034887 A KR1020237034887 A KR 1020237034887A KR 20237034887 A KR20237034887 A KR 20237034887A KR 20240004296 A KR20240004296 A KR 20240004296A
Authority
KR
South Korea
Prior art keywords
methyl
pyridin
cyclopropane
carboxamide
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237034887A
Other languages
English (en)
Korean (ko)
Inventor
니콜라오스 파파이오아노우
제러미 마크 트라빈스
사라 조설린 핑크
존 마크 엘라드
앨러스테어 래
조너선 앤드류 스펜서
스튜어트 셰인 랭킨
로버트 스튜어트 로리 채프먼
Original Assignee
다께다 파머수티컬 컴패니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다께다 파머수티컬 컴패니 리미티드 filed Critical 다께다 파머수티컬 컴패니 리미티드
Publication of KR20240004296A publication Critical patent/KR20240004296A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020237034887A 2021-03-17 2022-03-16 혈장 칼리크레인의 헤테로아릴 억제제 Pending KR20240004296A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163162468P 2021-03-17 2021-03-17
US63/162,468 2021-03-17
PCT/US2022/020482 WO2022197758A1 (en) 2021-03-17 2022-03-16 Heteroaryl inhibitors of plasma kallikrein

Publications (1)

Publication Number Publication Date
KR20240004296A true KR20240004296A (ko) 2024-01-11

Family

ID=81328275

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237034887A Pending KR20240004296A (ko) 2021-03-17 2022-03-16 혈장 칼리크레인의 헤테로아릴 억제제

Country Status (10)

Country Link
US (1) US20240228488A1 (cg-RX-API-DMAC10.html)
EP (2) EP4585265A3 (cg-RX-API-DMAC10.html)
JP (1) JP2024516073A (cg-RX-API-DMAC10.html)
KR (1) KR20240004296A (cg-RX-API-DMAC10.html)
CN (1) CN117355521A (cg-RX-API-DMAC10.html)
AU (1) AU2022240596A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023018619A2 (cg-RX-API-DMAC10.html)
CA (1) CA3208243A1 (cg-RX-API-DMAC10.html)
MX (1) MX2023011014A (cg-RX-API-DMAC10.html)
WO (1) WO2022197758A1 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112135825A (zh) 2018-03-13 2020-12-25 夏尔人类遗传性治疗公司 血浆激肽释放酶抑制剂及其用途
CN114728962B (zh) 2019-09-18 2025-09-19 武田药品工业有限公司 血浆激肽释放酶抑制剂及其用途
WO2021055589A1 (en) 2019-09-18 2021-03-25 Shire Human Genetic Therapies, Inc. Heteroaryl plasma kallikrein inhibitors
WO2022197755A1 (en) * 2021-03-17 2022-09-22 Shire Human Genetic Therapies, Inc. Imidazopyridinyl inhibitors of plasma kallikrein
EP4585265A3 (en) 2021-03-17 2025-10-15 Takeda Pharmaceutical Company Limited Heteroaryl inhibitors of plasma kallikrein
JP2025531158A (ja) * 2022-09-21 2025-09-19 武田薬品工業株式会社 シクロプロパンカルボン酸の合成
EP4735442A1 (en) * 2023-06-29 2026-05-06 Theranib Inc. IMIDAZO[1,2-alpha]PYRIDINE COMPOUNDS FOR USE IN TREATING CANCER AND INFLAMMATORY DISEASES AND METHODS TO PREPARE SAID COMPOUNDS
CN117069662A (zh) * 2023-10-17 2023-11-17 峰成医药科技(天津)有限公司 一种4,6-二氯-2-(二氟甲基)嘧啶的合成方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
DK0495421T3 (da) 1991-01-15 1996-12-09 Alcon Lab Inc Anvendelse af carragenaner i topiske ophthalmiske sammensætninger
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
GB201421088D0 (en) * 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
US9815853B2 (en) * 2015-06-12 2017-11-14 Global Blood Therapeutics, Inc. Bridged bicyclic kallikrein inhibitors
CN112135825A (zh) * 2018-03-13 2020-12-25 夏尔人类遗传性治疗公司 血浆激肽释放酶抑制剂及其用途
EP4585265A3 (en) 2021-03-17 2025-10-15 Takeda Pharmaceutical Company Limited Heteroaryl inhibitors of plasma kallikrein

Also Published As

Publication number Publication date
MX2023011014A (es) 2023-12-06
BR112023018619A2 (pt) 2023-11-28
CA3208243A1 (en) 2022-09-22
CN117355521A (zh) 2024-01-05
EP4585265A2 (en) 2025-07-16
AU2022240596A1 (en) 2023-10-19
US20240228488A1 (en) 2024-07-11
JP2024516073A (ja) 2024-04-12
EP4585265A3 (en) 2025-10-15
EP4308230A1 (en) 2024-01-24
WO2022197758A1 (en) 2022-09-22

Similar Documents

Publication Publication Date Title
US11084831B1 (en) Benzopiperazine compositions as BET bromodomain inhibitors
US11111229B2 (en) Tetrahydroquinoline compositions as BET bromodomain inhibitors
US10538533B2 (en) Heteroaryls and uses thereof
US20240262806A1 (en) Inhibitors of nlrp3
WO2022197758A1 (en) Heteroaryl inhibitors of plasma kallikrein
US12065445B2 (en) CDK2 inhibitors and methods of using the same
US20130059834A1 (en) Pyrrolopyrazine kinase inhibitors
JP2018531213A6 (ja) Hdac8阻害剤としてのアルファ−シンナミド化合物及び組成物
JP2018531213A (ja) Hdac8阻害剤としてのアルファ−シンナミド化合物及び組成物
US20160256458A1 (en) Benzopiperazine compositions as bet bromodomain inhibitors
US20160256448A1 (en) Tetrahydroquinoline compositions as bet bromodomain inhibitors
US20240343704A1 (en) Halo-substituted amino pyridine compounds as inhibitors of the haematopoietic progenitor kinase 1 (hpk1)
US20180057505A1 (en) Bicyclic heteroaryl compounds useful as inhibitors of the par-2 signaling pathway
US20260125400A1 (en) Tyk2 degraders and uses thereof
JP2025531207A (ja) 遺伝性血管性浮腫の処置のための血漿カリクレイン阻害剤としてのn-((イソキノリン-6イル)メチル)-1h-ピラゾール-4-カルボキサミド誘導体
TW202547512A (zh) Sik2調節劑及其用途
TW202208354A (zh) PI3Kα抑制劑及其使用方法
HK1229244A1 (en) Benzopiperazine compositions as bet bromodomain inhibitors
HK1229244B (en) Benzopiperazine compositions as bet bromodomain inhibitors

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20231012

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250313

Comment text: Request for Examination of Application